دورية أكاديمية
Niridazole biodegradable inserts for local long-term treatment of periodontitis: possible new life for an orphan drug.
| العنوان: | Niridazole biodegradable inserts for local long-term treatment of periodontitis: possible new life for an orphan drug. |
|---|---|
| المؤلفون: | Barat R; Ranbaxy Research Laboratories, Gurgaon, India., Srinatha A, Pandit JK, Ridhurkar D, Balasubramaniam J, Mittal N, Mishra DN |
| المصدر: | Drug delivery [Drug Deliv] 2006 Sep-Oct; Vol. 13 (5), pp. 365-73. |
| نوع المنشور: | Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9417471 Publication Model: Print Cited Medium: Print ISSN: 1071-7544 (Print) Linking ISSN: 10717544 NLM ISO Abbreviation: Drug Deliv Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015->: Abingdon, Oxford : Taylor & Francis Original Publication: Orlando, FL : Academic Press, c1993- |
| مواضيع طبية MeSH: | Absorbable Implants*, Niridazole/*therapeutic use , Periodontitis/*drug therapy, Adolescent ; Adult ; Drug Carriers ; Gingival Hemorrhage/drug therapy ; Gingival Hemorrhage/prevention & control ; Humans ; Middle Aged ; Niridazole/blood ; Niridazole/pharmacokinetics ; Orphan Drug Production ; Periodontal Index ; Pilot Projects ; Time Factors ; Treatment Outcome |
| مستخلص: | Periodontal pocket inserts of niridazole (NZ) made with Resomer(R) (grades RG 503H and RG858, designated as RH and RG, respectively) were studied. Various formulation variables were evaluated to obtain a biodegradable delivery systems showing device degradation and drug depletion parallel to each other in vitro. Drug release from the prepared inserts was evaluated using a static dissolution setup (for 1 month). Incorporation of 3 parts of RG in 1 part of RH inserts caused a 50% decrease in the initial release rate. The RH-NZ inserts showed a spurt in release around the 10th day of the study, which coincided with the decrease in device weight, suggesting onset of device degradation. Pilot-scale clinical trials in 12 patients indicated improvements in clinical indices from the baseline values. The average pocket depth was reduced significantly (alpha = 0.05) from 6.34 +/- 1.86 mm at baseline to 5.94 +/- 0.28 mm after 28 days of treatment. |
| المشرفين على المادة: | 0 (Drug Carriers) N116U8Y5QQ (Niridazole) |
| تواريخ الأحداث: | Date Created: 20060801 Date Completed: 20061102 Latest Revision: 20190516 |
| رمز التحديث: | 20240829 |
| DOI: | 10.1080/10717540500398126 |
| PMID: | 16877312 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1071-7544 |
|---|---|
| DOI: | 10.1080/10717540500398126 |